TransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance

MT Newswires Live2024-12-03

TransMedics (TMDX) said Monday it named Gerardo Hernandez as chief financial officer.

Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals (ALNY), TransMedics said.

Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.

Gordon will then become a non-employee senior advisor to TransMedics focusing on national transplant stakeholder engagement until March 31, 2026, the company said.

TransMedics also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.

Analysts polled by Factset expect $431.9 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488894469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 05:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488894469","market":"nz","top_or_hot":-1,"title":"TransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance","media":"MT Newswires Live","content":"<html><body><p> TransMedics (TMDX) said Monday it named Gerardo Hernandez as chief financial officer.</p><p>Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals (ALNY), TransMedics said.</p><p>Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.</p><p>Gordon will then become a non-employee senior advisor to TransMedics focusing on national transplant stakeholder engagement until March 31, 2026, the company said.</p><p>TransMedics also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.</p><p>Analysts polled by Factset expect $431.9 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransMedics Names Gerardo Hernandez as CFO; Updates Full Year 2024 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 05:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TransMedics (TMDX) said Monday it named Gerardo Hernandez as chief financial officer.Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488894469","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488894469","pubTimestamp":1733176184,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransMedics  said Monday it named Gerardo Hernandez as chief financial officer.Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals , TransMedics said.Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.Gordon will then become a non-employee senior advisor to TransMedics focusing on national transplant stakeholder engagement until March 31, 2026, the company said.TransMedics also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.Analysts polled by Factset expect $431.9 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"TransMedics任命Gerardo Hernandez为首席财务官；更新2024年全年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1,"TMDX":0.9},"content_text":"TransMedics (TMDX) said Monday it named Gerardo Hernandez as chief financial officer.Hernandez was most recently vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals (ALNY), TransMedics said.Hernandez succeeds Stephen Gordon, who will remain a non-executive employee until March 31, 2025.Gordon will then become a non-employee senior advisor to TransMedics focusing on national transplant stakeholder engagement until March 31, 2026, the company said.TransMedics also said it now expects full-year 2024 revenue between $428 million and $432 million, which is a 77% to 79% increase compared with its previous year revenue.Analysts polled by Factset expect $431.9 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488894469"}